Are mesenchymal stem cells major sources of safe signals in immune system?

Cellular Immunology

Volumn 272, Issue 2, 2012, Pages 112-116

  Wang, Hanyu ^a   Wu, Mingyuan ^b,c   Liu, Yongjun ^a,c  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c Alliancells Institute of Stem Cells Translational Regenerative Medicine   (China)

Author keywords

Autoimmune diseases; Mesenchymal stem cells; Safe signals

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 10; PROSTAGLANDIN E2; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

CD25+ T LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRUCTURE; CELL THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SENESCENCE; SIGNAL TRANSDUCTION; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNE SYSTEM; MESENCHYMAL STEM CELLS; TISSUE THERAPY;

EID: 83955165259     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.10.010     Document Type: Review

References (84)

1. Burnet M. Auto-immune disease. I. Modern immunological concepts. Br. Med. J. 1959, 2:645-650.
2. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
3. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 2001, 13:114-119.
4. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 1995, 182:389-400.
5. Caux C., Massacrier C., Vanbervliet B., Dubois B., Van Kooten C., Durand I., Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 1994, 180:1263-1272.
6. Krieg A.M. The role of CpG motifs in innate immunity. Curr. Opin. Immunol. 2000, 12:35-43.
7. De Ugarte D.A., Alfonso Z., Zuk P.A., Elbarbary A., Zhu M., Ashjian P., Benhaim P., Hedrick M.H., Fraser J.K. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol. Lett. 2003, 89:267-270.
8. Hong S.H., Gang E.J., Jeong J.A., Ahn C., Hwang S.H., Yang I.H., Park H.K., Han H., Kim H. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem. Biophys. Res. Commun. 2005, 330:1153-1161.
9. Covas D.T., Siufi J.L., Silva A.R., Orellana M.D. Isolation and culture of umbilical vein mesenchymal stem cells. Braz. J. Med. Biol. Res. 2003, 36:1179-1183.
10. Mihu C.M., Rus Ciuca D., Soritau O., Susman S., Mihu D. Isolation and characterization of mesenchymal stem cells from the amniotic membrane. Rom. J. Morphol. Embryol. 2009, 50:73-77.
11. Zhang Q., Shi S., Liu Y., Uyanne J., Shi Y., Le A.D. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J. Immunol. 2009, 183:7787-7798.
12. Siepe M., Thomsen A.R., Duerkopp N., Krause U., Forster K., Hezel P., Beyersdorf F., Schlensak C., Sudkamp N.P., Bosse R., Niemeyer P. Human neonatal thymus-derived mesenchymal stromal cells: characterization, differentiation, and immunomodulatory properties. Tissue Eng. Part A 2009, 15:1787-1796.
13. Miao Z., Jin J., Chen L., Zhu J., Huang W., Zhao J., Qian H., Zhang X. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol. Int. 2006, 30:681-687.
14. Sakaguchi Y., Sekiya I., Yagishita K., Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 2005, 52:2521-2529.
15. Campagnoli C., Roberts I.A., Kumar S., Bennett P.R., Bellantuono I., Fisk N.M. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98:2396-2402.
16. Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2005, 11:321-334.
17. Tasso R., Pennesi G. When stem cells meet immunoregulation. Int. Immunopharmacol. 2009, 9:596-598.
18. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
19. Muraro P.A., Uccelli A. Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. Results Probl. Cell Differ. 2010, 51:237-257.
20. Ding Y., Bushell A., Wood K.J. Mesenchymal stem-cell immunosuppressive capabilities: therapeutic implications in islet transplantation. Transplantation 2010, 89:270-273.
21. Itakura S., Asari S., Rawson J., Ito T., Todorov I., Liu C.P., Sasaki N., Kandeel F., Mullen Y. Mesenchymal stem cells facilitate the induction of mixed hematopoietic chimerism and islet allograft tolerance without GVHD in the rat. Am. J. Transplant. 2007, 7:336-346.
22. Baron F., Lechanteur C., Willems E., Bruck F., Baudoux E., Seidel L., Vanbellinghen J.F., Hafraoui K., Lejeune M., Gothot A., Fillet G., Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 2010, 16:838-847.
23. Aksu A.E., Horibe E., Sacks J., Ikeguchi R., Breitinger J., Scozio M., Unadkat J., Feili-Hariri M. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin. Immunol. 2008, 127:348-358.
24. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
25. Augello A., Tasso R., Negrini S.M., Cancedda R., Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007, 56:1175-1186.
26. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
27. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
28. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
29. Ge W., Jiang J., Arp J., Liu W., Garcia B., Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010, 90:1312-1320.
30. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D., Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem cells 2008, 26:212-222.
31. Sato K., Ozaki K., Oh I., Meguro A., Hatanaka K., Nagai T., Muroi K., Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
32. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., Zhao R.C., Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
33. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
34. Chen K., Wang D., Du W.T., Han Z.B., Ren H., Chi Y., Yang S.G., Zhu D., Bayard F., Han Z.C. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin. Immunol. 2010, 135:448-458.
35. Glennie S., Soeiro I., Dyson P.J., Lam E.W., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
36. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 2003, 171:3426-3434.
37. Ramasamy R., Fazekasova H., Lam E.W., Soeiro I., Lombardi G., Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007, 83:71-76.
38. Munn D.H., Armstrong E. Cytokine regulation of human monocyte differentiation in vitro: the tumor-cytotoxic phenotype induced by macrophage colony-stimulating factor is developmentally regulated by gamma-interferon. Cancer Res. 1993, 53:2603-2613.
39. Munn D.H., Pressey J., Beall A.C., Hudes R., Alderson M.R. Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. A potential mechanism of antigen-specific peripheral lymphocyte deletion. J. Immunol. 1996, 156:523-532.
40. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196:459-468.
41. Terness P., Bauer T.M., Rose L., Dufter C., Watzlik A., Simon H., Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002, 196:447-457.
42. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 2000, 164:3596-3599.
43. Kamimura S., Eguchi K., Yonezawa M., Sekiba K. Localization and developmental change of indoleamine 2,3-dioxygenase activity in the human placenta. Acta Med. Okayama 1991, 45:135-139.
44. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
45. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
46. Goodwin J.S., Bankhurst A.D., Messner R.P. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J. Exp. Med. 1977, 146:1719-1734.
47. Harris S.G., Padilla J., Koumas L., Ray D., Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 2002, 23:144-150.
48. Minakuchi R., Wacholtz M.C., Davis L.S., Lipsky P.E. Delineation of the mechanism of inhibition of human T cell activation by PGE2. J. Immunol. 1990, 145:2616-2625.
49. Anastassiou E.D., Paliogianni F., Balow J.P., Yamada H., Boumpas D.T. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J. Immunol. 1992, 148:2845-2852.
50. Nataraj C., Thomas D.W., Tilley S.L., Nguyen M.T., Mannon R., Koller B.H., Coffman T.M. Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J. Clin. Invest. 2001, 108:1229-1235.
51. Baratelli F., Lin Y., Zhu L., Yang S.C., Heuze-Vourc'h N., Zeng G., Reckamp K., Dohadwala M., Sharma S., Dubinett S.M. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J. Immunol. 2005, 175:1483-1490.
52. Mahic M., Yaqub S., Johansson C.C., Tasken K., Aandahl E.M. FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 2006, 177:246-254.
53. Kamei T., Callery M.P., Flye M.W. Intragraft delivery of 16, 16-dimethyl PGE2 induces donor-specific tolerance in rat cardiac allograft recipients. Transplantation 1991, 51:242-246.
54. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol. Lett. 2007, 110:91-100.
55. Jarvinen L., Badri L., Wettlaufer S., Ohtsuka T., Standiford T.J., Toews G.B., Pinsky D.J., Peters-Golden M., Lama V.N. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J. Immunol. 2008, 181:4389-4396.
56. Morandi F., Raffaghello L., Bianchi G., Meloni F., Salis A., Millo E., Ferrone S., Barnaba V., Pistoia V. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem cells 2008, 26:1275-1287.
57. Jarnicki A.G., Lysaght J., Todryk S., Mills K.H. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 2006, 177:896-904.
58. Okunishi K., Dohi M., Nakagome K., Tanaka R., Mizuno S., Matsumoto K., Miyazaki J., Nakamura T., Yamamoto K. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J. Immunol. 2005, 175:4745-4753.
59. Kuroiwa T., Kakishita E., Hamano T., Kataoka Y., Seto Y., Iwata N., Kaneda Y., Matsumoto K., Nakamura T., Ueki T., Fujimoto J., Iwasaki T. Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J. Clin. Invest. 2001, 107:1365-1373.
60. Gieseke F., Schutt B., Viebahn S., Koscielniak E., Friedrich W., Handgretinger R., Muller I. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 2007, 110:2197-2200.
61. Markey K.A., Burman A.C., Banovic T., Kuns R.D., Raffelt N.C., Rowe V., Olver S.D., Don A.L., Morris E.S., Pettit A.R., Wilson Y.A., Robb R.J., Randall L.M., Korner H., Engwerda C.R., Clouston A.D., Macdonald K.P., Hill G.R. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood 2010, 115:122-132.
62. van den Brink M.R., Burakoff S.J. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2002, 2:273-281.
63. Ortiz L.A., Dutreil M., Fattman C., Pandey A.C., Torres G., Go K., Phinney D.G. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. USA 2007, 104:11002-11007.
64. Ame-Thomas P., Maby-El Hajjami H., Monvoisin C., Jean R., Monnier D., Caulet-Maugendre S., Guillaudeux T., Lamy T., Fest T., Tarte K. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 2007, 109:693-702.
65. Leo A.J., Grande D.A. Mesenchymal stem cells in tissue engineering. Cells Tissues Organs 2006, 183:112-122.
66. Minguell J.J., Erices A., Conget P. Mesenchymal stem cells. Exp. Biol. Med. (Maywood) 2001, 226:507-520.
67. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
68. Holler E., Kolb H.J., Moller A., Kempeni J., Liesenfeld S., Pechumer H., Lehmacher W., Ruckdeschel G., Gleixner B., Riedner C., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990, 75:1011-1016.
69. Hill G.R., Teshima T., Gerbitz A., Pan L., Cooke K.R., Brinson Y.S., Crawford J.M., Ferrara J.L. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J. Clin. Invest. 1999, 104:459-467.
70. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
71. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
72. Granger G.A., Williams T.W. Lymphocyte cytotoxicity in vitro: activation and release of a cytotoxic factor. Nature 1968, 218:1253-1254.
73. Williams T.W., Granger G.A. Lymphocyte in vitro cytotoxicity: lymphotoxins of several mammalian species. Nature 1968, 219:1076-1077.
74. Paul N.L., Ruddle N.H. Lymphotoxin. Annu. Rev. Immunol. 1988, 6:407-438.
75. Calmon-Hamaty F., Combe B., Hahne M., Morel J. Lymphotoxin alpha stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 2011, 53:207-214.
76. Buch M.H., Conaghan P.G., Quinn M.A., Bingham S.J., Veale D., Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?. Ann. Rheum. Dis. 2004, 63:1344-1346.
77. Chiang E.Y., Kolumam G.A., Yu X., Francesco M., Ivelja S., Peng I., Gribling P., Shu J., Lee W.P., Refino C.J., Balazs M., Paler-Martinez A., Nguyen A., Young J., Barck K.H., Carano R.A., Ferrando R., Diehl L., Chatterjea D., Grogan J.L. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat. Med. 2009, 15:766-773.
78. Carrion F., Nova E., Ruiz C., Diaz F., Inostroza C., Rojo D., Monckeberg G., Figueroa F.E. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010, 19:317-322.
79. Nie Y., Lau C., Lie A., Chan G., Mok M. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010, 19:850-859.
80. Kastrinaki M.C., Sidiropoulos P., Roche S., Ringe J., Lehmann S., Kritikos H., Vlahava V.M., Delorme B., Eliopoulos G.D., Jorgensen C., Charbord P., Haupl T., Boumpas D.T., Papadaki H.A. Functional molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann. Rheum. Dis. 2008, 67:741-749.
81. Kemp K., Morse R., Wexler S., Cox C., Mallam E., Hows J., Donaldson C. Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy. Ann. Hematol. 2010, 89:701-713.
82. Perez-Simon J.A., Tabera S., Sarasquete M.E., Diez-Campelo M., Canchado J., Sanchez-Abarca L.I., Blanco B., Alberca I., Herrero-Sanchez C., Canizo C., San Miguel J.F. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy 2009, 1-8.
83. Bacigalupo A., Valle M., Podesta M., Pitto A., Zocchi E., De Flora A., Pozzi S., Luchetti S., Frassoni F., Van Lint M.T., Piaggio G. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp. Hematol. 2005, 33:819-827.
84. Arnulf B., Lecourt S., Soulier J., Ternaux B., Lacassagne M.N., Crinquette A., Dessoly J., Sciaini A.K., Benbunan M., Chomienne C., Fermand J.P., Marolleau J.P., Larghero J. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007, 21:158-163.